A Phase II, Double-Blind, Crossover Study to Assess the Efficacy and Safety of 10% (150mg) Lidocaine Vaginal Gel Administered to Women With Recurrent Dysmenorrhea
Phase of Trial: Phase II
Latest Information Update: 07 May 2015
At a glance
- Drugs Lidocaine (Primary)
- Indications Dysmenorrhoea
- Focus Adverse reactions; Therapeutic Use
- Sponsors Columbia Laboratories
- 29 Sep 2008 Interim results reported in a Columbia media release. Complete analysis of secondary data ongoing.
- 08 Sep 2008 Status changed from active, no longer recruiting to completed according to Columbia Laboratories media release.
- 08 Sep 2008 Top-line results available 29 Sep 2008 according to Columbia Laboratories media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History